Roldan, Paola
Ravi, Sriram
Hodovan, James
Belcik, J. Todd
Heitner, Stephen B.
Masri, Ahmad
Lindner, Jonathan R.
Funding for this research was provided by:
National Institutes of Health (R01-HL078610; R01-HL130046)
Article History
Received: 18 May 2022
Accepted: 13 August 2022
First Online: 19 September 2022
Declarations
:
: The study was approved by the Investigational Review Board at Oregon Health & Science University (IRB 00015158). All subjects gave written informed consent to participate.
: Not applicable.
: Material support was provided by Bracco Pharmaceuticals, Princeton, NJ (Lumason ultrasound contrast agent) and by Astellas Pharma, Tokyo, Japan (Lexiscan [regadenoson]). No other financial or non-financial competing interests exist for any of the authors.